FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients with significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia.
Slovenian: Bolniki s pomembno okvaro funkcije kostnega mozga ali pomembno anemijo, levkopenijo, nevtropenijo ali trombocitopenijo.
English: From the mean predicted pharmacokinetic parameters calculated from the population pharmacokinetic (PopPK) analysis using data from healthy volunteers and MS patients, there is a slow approach to steadystate concentration (i.e., approximately 100 days (3.5 months) to attain 95% of steady-state concentrations) and the estimated AUC accumulation ratio is approximately 34-fold.
Slovenian: Od povprečnih napovedanih farmakokinetičnih parametrov, izračunanih iz populacijske farmakokinetične (PopPK) analize s podatki, pridobljenimi pri zdravih prostovoljcih in bolnikih z MS, sledi počasen prehod do koncentracije v stanju dinamičnega ravnovesja (tj. približno 100 dni (3,5 meseca) do 95-odstotne koncentracije v stanju dinamičnega ravnovesja ), ocenjeno razmerje akumulacije AUC je približno 34kratno.
English: If both plasma concentrations are below 0.02 mg/l, no risk to the foetus is to be expected.
Slovenian: Če sta obe določitvi plazemske koncentracije pod 0,02 mg/l, tveganja za plod ni pričakovati.
English: Potent cytochrome P450 (CYP) and transporter inducers Co-administration of repeated doses (600 mg once daily for 22 days) of rifampicin (a CYP2B6, 2C8, 2C9, 2C19, 3A inducer), as well as an inducer of the efflux transporters P-glycoprotein [P-gp] and breast cancer resistant protein [BCRP] with teriflunomide (70 mg single dose) resulted in an approximately 40% decrease in teriflunomide exposure.
Slovenian: Močni induktorji citokroma P450 (CYP) in transporterjev: očasno dajanje ponavljajočih se odmerkov (600 mg enkrat dnevno 22 dni) rifampicina (induktorja CYP2B6, 2C8, 2C9, 2C19, 3A) in induktorja iztočnih transporterjev glikoproteina P [P-gp] in beljakovine, odporne za raka dojke [BCRP], skupaj s teriflunomidom (70 mg enkratni odmerek) je privedlo do približno 40 % nižje izpostavljenosti teriflunomidu.
English: Within this safety population, the most commonly reported adverse reactions in the teriflunomide treated patients were: headache, diarrhoea, increased ALT, nausea, and alopecia.
Slovenian: V tej populaciji za oceno varnosti so bili najpogosteje poročani neželeni učinki pri bolnikih, zdravljenih s teriflunomidom: glavobol, driska, zvišana raven ALT, navzea in alopecija.
English: TOPIC was a double-blind, placebo-controlled study that evaluated once daily doses of teriflunomide 7 mg and 14 mg for up to 108 weeks in patients with first clinical demyelinating event (mean age 32.1 years).
Slovenian: Raziskava TOPIC je bila dvojno slepa, s placebom kontrolirana študija, ki je ocenjevala odmerka 7 mg in 14 mg teriflunomida enkrat na dan v obdobju do 108 tednov pri bolnikih s prvim kliničnim demielinizirajočim dogodkom (povprečna starost 32,1 let).
English: A total of 2267 patients were exposed to teriflunomide (1155 on teriflunomide 7 mg and 1112 on teriflunomide 14 mg) once daily for a median duration of about 672 days in four placebo-controlled studies (1045 and 1002 patients for teriflunomide 7 mg and 14 mg, respectively) and one active comparator study (110 patients in each of the teriflunomide treatment groups) in patients with relapsing forms of MS (Relapsing Multiple Sclerosis, RMS).
Slovenian: Skupno 2267 bolnikov je bilo izpostavljeno teriflunomidu (1155 bolnikov odmerku 7 mg teriflunomida in 1112 bolnikov odmerku 14 mg teriflunomida) enkrat dnevno v obdobju z mediano trajanja približno 672 dni v štirih s placebom kontroliranih študijah (1045 bolnikov z odmerkom 7 mg teriflunomida in 1002 bolnika z odmerkom 14 mg teriflunomida) in eni študiji z aktivnim primerjalnim zdravilom (110 bolnikov v vsaki skupini, ki je prejemala teriflunomid) pri bolnikih z recidivnimi oblikami MS (recidivna multipla skleroza, RMS - Relapsing Multiple Sclerosis).
English: Teriflunomide effectiveness was compared to that of a subcutaneous interferon beta-1a (at the recommended dose of 44 µg three times a week) in 324 randomised patients in a study (TENERE) with minimum treatment duration of 48 weeks (maximum 114 weeks).
Slovenian: Učinkovitost teriflunomida so primerjali s subkutano uporabljenim interferonom beta-1a (v priporočenem odmerku 44 µg trikrat na teden) pri 324 naključno razporejenih bolnikih v študiji (TENERE) z najkrajšim trajanjem 48 tednov (največ 114 tednov).
English: Blood pressure effects
Slovenian: Učinki na krvni tlak
English: The placebo-controlled pooled analysis was based on 2047 patients with Relapsing Multiple Sclerosis treated with teriflunomide once daily.
Slovenian: S placebom kontrolirana združena analiza je temeljila na 2047 bolnikih z recidivno multiplo sklerozo, ki so bili zdravljeni s teriflunomidom enkrat dnevno.
English: • Potential risk of teratogenicity o To check pregnancy status before starting treatment o To educate female patients of child-bearing potential on the need for effective contraception before starting, and during treatment with teriflunomide o To inform their doctor immediately if they stop contraception, or prior to changing contraceptive measures o If female patients become pregnant despite using contraceptive measures, they should stop teriflunomide and contact their doctor immediately who should: Consider and discuss with the patient the accelerated elimination procedure encourage them to enrol in a pregnancy registry (in countries where a pregnancy registry is on-going),
Slovenian: • možno tveganje teratogenosti o pred začetkom zdravljenja je treba preveriti stanje nosečnosti, o bolnice v rodni dobi je treba poučiti o potrebi po učinkoviti kontracepciji pred začetkom zdravljenja s teriflunomidom in med njim, o zdravnika morajo takoj obvestiti, če prekinejo ali spremenijo kontracepcijo, o če kljub uporabi kontracepcije bolnice zanosijo, morajo prenehati jemati teriflunomid in nemudoma obvestiti svojega zdravnika, ki mora: razmisliti o postopku pospešenega izločanja in se o tem pogovoriti z bolnico, jih spodbujati za vključitev v register nosečnosti (v državah, kjer register nosečnosti obstaja),
English: The recommended elimination procedure is cholestyramine 8 g three times a day for 11 days.
Slovenian: Pri priporočenem postopku izločanja dajemo holestiramin 8 g trikrat na dan, 11 dni.
English: Immune system
Slovenian: Imunski sistem
English: In patients treated with leflunomide, the parent compound, very rare cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported.
Slovenian: Pri bolnikih zdravljenih z leflunomidom, starševsko spojino, so poročali tudi o zelo redkih primerih neželene reakcije z eozinofilijo in sistemskimi simptomi (sindrom DRESS - Drug Reaction with Eosinophilia and Systemic Symptoms).
English: The European Medicines Agency has deferred the obligation to submit the results of studies with AUBAGIO in one or more subsets of the paediatric population in multiple sclerosis (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je začasno odložila obvezo za predložitev rezultatov študij z zdravilom AUBAGIO za eno ali več podskupin pediatrične populacije z multiplo sklerozo (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Based on the clinical data related to concomitant administration of teriflunomide with interferon beta or with glatiramer acetate, no waiting period is required when initiating teriflunomide after interferon beta or glatiramer acetate or when starting interferon beta or glatiramer acetate, after teriflunomide.
Slovenian: Na osnovi kliničnih podatkov v zvezi s sočasno uporabo teriflunomida in interferona beta ali glatiramer acetata ni potrebno čakati, če želite uvesti teriflunomid po zdravljenju z interferonom beta ali glatiramer acetatom ali če želite uvesti interferon beta ali glatiramer acetat po zdravljenju s teriflunomidom.
English: Therefore, medicinal products metabolised by CYP1A2 (such as duloxetin, alosetron, theophylline and tizanidine) should be used with caution during treatment with teriflunomide, as it could lead to the reduction of the efficacy of these medicinal products.
Slovenian: Zato je treba zdravila, ki se presnavljajo s CYP1A2 (kot so duloksetin, alosetron, teofilin in tizanidin), med zdravljenjem s teriflunomidom uporabljati previdno, saj lahko sočasna uporaba privede do zmanjšanja učinkovitosti navedenih zdravil.
English: The adverse reactions were consistent with the safety profile for teriflunomide in MS patients.
Slovenian: Neželeni učinki so bili skladno z varnostnim profilom teriflunomida pri bolnikih z MS.
English: The number of patients with permanent treatment discontinuation in the subcutaneous interferon beta-1a group was 30 out of 104 (28 .8%), the reasons being adverse events (21.2%), lack of efficacy (1.9%), other reason (4.8%) and poor compliance to protocol (1%).
Slovenian: Število bolnikov s trajno prekinitvijo zdravljenja v skupini, ki je prejemala subkutani interferon beta-1a, je bilo 30 od 104 (28,8 %), razlogi pa so bili neželeni učinki (21,2 %), pomanjkanje učinkovitosti (1,9 %), drugi razlogi (4,8 %) in nespoštovanje protokola (1 %).
English: If skin and /or mucosal reactions are observed which raise the suspicion of severe generalised major skin reactions (Stevens-Johnson syndrome, or toxic epidermal necrolysis-Lyell's syndrome), teriflunomide and any other possibly associated treatment must be discontinued, and an accelerated procedure initiated immediately.
Slovenian: Če ugotovite kožne in/ali sluznične reakcije, ki vzbudijo sum hudih generaliziranih poglavitnih kožnih reakcij (Stevens-Johnsonov sindrom ali toksična epidermalna nekroliza-Lyellov sindrom), je treba prekiniti zdravljenje s teriflunomidom in drugimi možno povezanimi zdravljenji.
English: A majority of patients (67.2%) had not received disease-modifying therapy during the 2 years before study entry.
Slovenian: Večina bolnikov (67,2 %) ni prejemala imunomodulirajočih sredstev 2 leti pred vključitvijo v raziskavo.
English: • Risk of hypertension o to check for a history of hypertension and that blood pressure should be appropriately managed during treatment o the need for blood pressure checks before treatment and periodically during treatment,
Slovenian: • tveganje za hipertenzijo o preveriti je treba anamnezo hipertenzije in da je krvni tlak med zdravljenjem ustrezno obvladovan, o krvni tlak je treba preverjati pred začetkom zdravljenja in redno med zdravljenjem,
English: Teriflunomide 14 mg/day was not superior to interferon beta1a on the primary endpoint: the estimated percentage of patients with treatment failure at 96 weeks using the Kaplan-Meier method was 41.1% versus 44.4% (teriflunomide 14 mg versus interferon beta-1a group, p=0.595).
Slovenian: V primarni končni točki odmerek 14 mg teriflunomida na dan ni bil statistično superioren od interferona beta-1a: ocenjen odstotek bolnikov z neuspešnim zdravljenjem po 96 tednih s Kaplan-Meierjevo metodo je bil 41,1 % v primerjavi s 44,4 % (teriflunomid 14 mg v primerjavi z interferonom beta-1a, p = 0,595).
English: No data are available in patients who have failed to respond to a full and adequate course (normally at least one year of treatment) of beta-interferon, having had at least 1 relapse in the previous year while on therapy, and at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion, or patients having an unchanged or increased relapse rate in the prior year as compared to the previous 2 years.
Slovenian: Ni podatkov o bolnikih, ki se niso odzvali na celoten in ustrezen ciklus (običajno najmanj eno leto zdravljenja) z interferonom beta, ki so v preteklem letu med zdravljenjem imeli vsaj 1 recidiv in vsaj 9 T2 hiperintenzivnih lezij v kranialnem MRS ali vsaj 1 lezijo po gadolinijevem kontrastiranju oz. bolnikih, ki so imeli nespremenjeno ali povečano stopnjo recidivov v predhodnem letu v primerjavi s preteklimi dvemi leti.
English: • For women of child-bearing potential o to emphasise the need for effective contraception during treatment with teriflunomide o to stop treatment with teriflunomide immediately if they suspect they might be pregnant and also to contact their doctor immediately
Slovenian: • za ženske v rodni dobi o poudariti potrebo po učinkoviti kontracepciji med zdravljenjem s teriflunomidom o zdravljenje s teriflunomidom je treba nemudoma prekiniti, če ženske sumijo, da bi lahko bile noseče in tudi da se takoj posvetujejo s svojim zdravnikom.
English: Once the teriflunomide plasma concentration is determined to be below 0.02 mg/l, the plasma concentration must be determined again after an interval of at least 14 days.
Slovenian: Ko se ugotovi, da je plazemska koncentracija teriflunomida pod 0,02 mg/l, je treba plazemsko koncentracijo še enkrat določiti po presledku vsaj 14 dni.
English: Systemic exposure increases in a dose proportional manner after oral administration teriflunomide from 7 to 14 mg.
Slovenian: Sistemska izpostavljenost se povečuje odvisno od odmerka po peroralni uporabi teriflunomida od 7 do 14 mg.
English: In case of ulcerative stomatitis, teriflunomide administration should be discontinued.
Slovenian: V primeru pojava ulcerativnega stomatitisa je treba dajanje teriflunomida prekiniti.
English: Haematological effects
Slovenian: Hematološki učinki
English: 14 film-coated tablets 28 film-coated tablets 84 (3 wallets of 28) film-coated tablets 98 (7 wallets of 14) film-coated tablets 10x1 film-coated tablet
Slovenian: 84 (3 pretisne zgibanke po 28) filmsko obloženih tablet 98 (7 pretisnih zgibank po 14) filmsko obloženih tablet 10 x 1 filmsko obložena tableta
English: The decrease in mean count from baseline occurred during the first 6 weeks then stabilised over time while on-treatment but at decreased levels (less than a 15% decrease from baseline).
Slovenian: Povprečno število se je iz izhodišča znižalo v prvih 6 tednih, nato pa se je s časom med zdravljenjem stabiliziralo na znižanih ravneh (na ravni manj kot 15 % pod izhodiščem).
English: The efficacy of AUBAGIO was demonstrated in two placebo controlled studies, the TEMSO and the TOWER study, that evaluated once daily doses of teriflunomide 7 mg and 14 mg in patients with RMS.
Slovenian: Učinkovitost zdravila AUBAGIO je bila dokazana v dveh s placebom kontroliranih študijah, TEMSO in TOWER, v katerih so ocenjevali odmerka teriflunomida 7 mg in 14 mg enkrat dnevno pri bolnikih z RMS.
English: • To remind female patients to tell their doctor if breastfeeding
Slovenian: • opomnik za bolnice, da svojega zdravnika obvestijo, če dojijo;
English: There is no experience regarding teriflunomide overdose or intoxication in humans.
Slovenian: Izkušenj glede prevelikega odmerjanja ali zastrupitve s teriflunomidom pri ljudeh ni.
English: In placebo-controlled studies the following was established: - systolic blood pressure was >140 mm Hg in 19.9% of patients receiving 14 mg/day teriflunomide as compared to 15.5% receiving placebo; - systolic blood pressure was >160 mm Hg in 3.8% of patients receiving 14 mg/day teriflunomide as compared to 2.0% receiving placebo; - diastolic blood pressure was >90 mm Hg in 21.4% of patients receiving 14 mg/day teriflunomide as compared to 13.6% receiving placebo.
Slovenian: V s placebom kontroliranih študijah so ugotovili naslednje: - sistolični krvni tlak je bil > 140 mm Hg pri 19,9 % bolnikov, ki so prejemali odmerek 14 mg teriflunomida na dan, in pri 15,5 % bolnikov, ki so prejemali placebo; - sistolični krvni tlak je bil >160 mm Hg pri 3,8 % bolnikov, ki so prejemali odmerek 14 mg teriflunomida na dan, ter pri 2,0 % bolnikov, ki so prejemali placebo; - diasistolični krvni tlak je bil > 90 mm Hg pri 21,4 % bolnikov, ki so prejemali odmerek 14 mg teriflunomida na dan, in pri 13,6 % bolnikov, ki so prejemali placebo.
English: In the event of relevant overdose or toxicity, cholestyramine or activated charcoal is recommended to accelerate elimination.
Slovenian: V primeru pomembnega prevelikega odmerjanja je priporočljivo dajanje holestiramina ali aktiviranega oglja za pospešitev izločanja.
English: The risk is increased in patients who had a history of ILD when treated with leflunomide.
Slovenian: Tveganje je povečano pri bolnikih, ki so med zdravljenjem z leflunomidom imeli ILD v anamnezi.
English: For women receiving teriflunomide treatment, who wish to become pregnant, the medicinal product should be stopped and an accelerated elimination procedure is recommended in order to more rapidly achieve concentration below 0.02 mg/l (see below).
Slovenian: Če ženska, ki jemlje teriflunomid, želi zanositi, je priporočljiva prekinitev zdravljenja in uvedba postopka pospešenega izločanja, da se hitreje doseže upad koncentracije pod 0,02 mg/l (glejte nadaljevanje).
English: In such cases patients should not be re-exposed to teriflunomide (see section 4.3).
Slovenian: V teh primerih se bolnikov ne sme več izpostaviti teriflunomidu (glejte poglavje 4.3).
English: Elevation of blood pressure may occur during treatment with teriflunomide (see section 4.8).
Slovenian: Med zdravljenjem s teriflunomidom se lahko pojavi zvišan krvni tlak (glejte poglavje 4.8).
English: As a precaution, a recent complete blood cell count, including differential white blood cell count and platelets, should be available before the initiation of treatment with AUBAGIO and the complete blood cell count should be assessed during AUBAGIO therapy as indicated by clinical signs and symptoms (e.g., infections).
Slovenian: Kot previdnostni ukrep mora biti pred uvedbo zdravljenja z zdravilom AUBAGIO na voljo nedavna celotna krvna slika, vključno z diferencialno krvno sliko levkocitov in trombocitov, nato pa se celotna krvna slika določa med zdravljenjem z zdravilom AUBAGIO glede na znake in simptome (npr. okužbe).
English: Therefore, teriflunomide plasma concentrations should be measured before a woman begins to attempt to become pregnant.
Slovenian: Zato je treba pri ženski, preden poskusi zanositi, določiti plazemske koncentracije teriflunomida.
English: The European Medicines Agency has waived the obligation to submit the results of studies with AUBAGIO in children from birth to less than 10 years in treatment of multiple sclerosis (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z zdravilom AUBAGIO za zdravljenje multiple skleroze pri otrocih od rojstva do starosti manj kot 10 let (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Falsely low levels of calcium can be detected.
Slovenian: Pojavi se lahko lažno nizek izvid koncentracije kalcija.
English: • To record the first date of prescription and the contact details of their prescriber 3.
Slovenian: • da morajo zabeležiti datum začetka zdravljenja in kontaktne podatke njihovega zdravnika.
English: Calendar days Mon
Slovenian: Koledarski dnevi Pon
English: AUBAGIO is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).
Slovenian: Zdravilo AUBAGIO je indicirano za zdravljenje odraslih bolnikov z recidivno reminitentno multiplo sklerozo (MS) (za pomembne informacije o populaciji, za katero je bila dokazana učinkovitost, glejte poglavje 5.1).
English: Your doctor will check your blood pressure before the start of treatment and regularly thereafter.
Slovenian: Vaš zdravnik bo redno preverjal vaš krvni tlak pred začetkom zdravljenja in med njim.
English: Pharmacotherapeutic group: Immunosuppressants, Selective immunosuppressants, ATC Code: L04AA31
Slovenian: Zdravila za selektivno zaviranje imunske odzivnosti, oznaka ATC: L04AA31.
English: In placebo-controlled studies, frequencies for asthenia were 2.0%, 1.6% and 2.2% in the placebo, teriflunomide 7 mg and teriflunomide 14 mg group, respectively.
Slovenian: V s placebom kontroliranih študijah je bila pogostnost za astenijo 2,0 %, 1,6 % ter 2,2 % pri bolnikih, ki so prejemali placebo, 7 mg teriflunomida ali 14 mg teriflunomida.
English: In placebo-controlled studies, no increase in serious infections was observed with teriflunomide 14 mg (2.7%) as compared to placebo (2.2%).
Slovenian: V s placebom nadzorovanih študijah pri teriflunomidu pri odmerku 14 mg (2,7 %) niso opazili nikakršnega povečanja resnih okužb v primerjavi s placebom (2,2 %).
English: Tablet coating hypromellose titanium dioxide (E171) talc macrogol 8000 indigo carmine aluminum lake (E132)
Slovenian: Obloga tablete hipromeloza titanov dioksid (E171) smukec makrogol 8000 indigotin (E132)
English: Repeated oral administration of teriflunomide to mice, rats and dogs for up to 3, 6, and 12 months, respectively, revealed that the major targets of toxicity were the bone marrow, lymphoid organs, oral cavity/ gastro intestinal tract, reproductive organs, and pancreas.
Slovenian: Ponavljajoče se peroralno odmerjanje teriflunomida mišim do 3 mesecev, podganam do 6 mesecev in psom do 12 mesecev je pokazalo, da so glavni tarčni organi toksičnosti kostni mozeg, limfoidni organi, ustna votlina/prebavila, reprodukcijski organi in trebušna slinavka.
English: If a patient taking AUBAGIO develops a confirmed peripheral neuropathy, consider discontinuing AUBAGIO therapy and performing the accelerated elimination procedure.
Slovenian: Če se pri bolniku, ki jemlje zdravilo AUBAGIO, pojavi potrjen primer periferne nevropatije, preučite možnost prekinitve zdravljenja z zdravilom AUBAGIO in opravite postopek pospešenega izločanja.
English: Based on the half-life of fingolimod, a 6-week interval without therapy is needed for clearance from the circulation and a 1 to 2 month period is needed for lymphocytes to return to normal range following discontinuation of fingolimod.
Slovenian: Na osnovi razpolovne dobe fingolimoda je po prekinitvi zdravljenja s fingolimodom potreben 6-tedenski presledek brez zdravljenja za očistek iz krvnega obtoka in 1- do 2-mesečno obdobje, da se število limfocitov vrne v normalno območje.
English: The number of patients with permanent treatment discontinuation in the teriflunomide 14 mg group was 22 out of 111 (19.8%), the reasons being adverse events (10.8%), lack of efficacy (3.6%), other reason (4.5%) and lost to follow-up (0.9%).
Slovenian: Število bolnikov s trajno prekinitvijo zdravljenja v skupini, ki je prejemala teriflunomid 14 mg je bilo 22 od 111 (19,8 %), razlogi pa so bili neželeni učinki (10,8 %), pomanjkanje učinkovitosti (3,6 %), drugi razlogi (4,5 %) in neuspešno spremljanje (0,9 %).
English: Food does not have a clinically relevant effect on teriflunomide pharmacokinetics.
Slovenian: Hrana nima klinično pomembnega učinka na farmakokinetiko teriflunomida.
English: Cases of severe skin reactions have been reported postmarketing (including Stevens-Johnson syndrome and toxic epidermal necrolysis).
Slovenian: V obdobju po prihodu zdravila na trg so pri uporabi teriflunomida poročali o hudih kožnih reakcijah (vključno s Stevens-Johnsonovim sindromom in toksično epidermalno nekrolizo).
English: Pale blue to pastel blue, pentagonal film-coated tablets with imprint on one side (‘14') and engraved with a corporate logo on the other side.
Slovenian: Bledo modre do pastelno modre, petkotne filmsko obložene tablete z napisom (‘14') na eni strani in vtisnjenim logotipom na drugi strani.
English: Therefore, when teriflunomide is coadministered with substrates of OAT3, such as cefaclor, benzylpenicillin, ciprofloxacin, indometacin, ketoprofen, furosemide, cimetidine, methotrexate, zidovudine, caution is recommended.
Slovenian: Zato je pri jemanju teriflunomida sočasno s substrati OAT3, kot so cefaklor, benzilpenicilin, ciprofloksacin, indometacin, ketoprofen, furosemid, cimetidin, metotreksat in zidovudin, priporočljiva previdnost.
English: The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is not fully understood, but this is mediated by a reduced number of lymphocytes.
Slovenian: Natančen mehanizem terapevtskega učinka teriflunomida pri MS ni pojasnjen, vendar se lahko razvije zaradi zmanjšanega števila limfocitov.